Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data.

Agathe Chabassier^1,2,3, Benjamin Vittrant³, Pierre Binon³, Erwan Scornet¹, Julie Josse²

¹Sorbonne University, CNRS, Laboratory of Probability Statistics and Modelling (LPSM), Paris, France.

²Inria, Inserm, PreMeDICaL Team, University of Montpellier, France.

³Withings, Issy-les-Moulineaux, France.

PubMed PMC DOI PDF

Abstract

OBJECTIVE: To characterize real-world body composition and blood pressure changes following glucagon-like peptide (GLP)-1 receptor agonist (RA) initiation and identify predictors of weight loss quality using connected device data. PATIENTS AND METHODS: In this retrospective cohort study, adult US users completing an in-application GLP-1 RA survey (June 8, 2023, to July 4, 2024) were followed up u…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.